Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Prescription of Strong Opioids in Chronic Non-Cancer Pain in the Province of Valladolid (Spain).
Life (Basel)
January 2025
Spaulding Rehabilitation Hospital, Department of Physical Medicine & Rehabilitation, Harvard Medical School, Boston, MA 02115, USA.
Chronic non-cancer pain (CNCP) is one of the leading causes of disability. The use of strong opioids (SOs) in the management of CNCP is increasing, although evidence supporting their use remains limited. Primary care (PC) plays a key role in this context.
View Article and Find Full Text PDFTapentadol Withdrawal Dystonia in a Young Adult Male Patient With Opioid Use Disorder.
J Clin Psychopharmacol
January 2024
Department of Psychiatry, All India Institute of Medical Sciences (AIIMS), Bathinda, India
Epidemiology of New Psychoactive Substances in Relation to Traditional Drugs of Abuse in Clinical Oral Fluid Samples.
Basic Clin Pharmacol Toxicol
February 2025
Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
New psychoactive substances (NPS) are health-hazardous through unpredictable toxicity and effects and largely unknown epidemiology, motivating studies of the latter. Up to 138 NPS were retrospectively identified using liquid chromatography-high resolution mass spectrometry data from all 34 183 oral fluid drug samples collected in one Swedish health care region 2019-2020 representing 9468 psychiatric and addiction care patients. In total, 618 findings representing 58 NPS were detected in 481 samples from 201 patients.
View Article and Find Full Text PDFTapentadol nasal spray dependence: A reticent subtype of opioid dependence?
Indian J Psychiatry
November 2024
Department of Psychiatry, Mahatma Gandhi Medical College and Research Institute, Sri Balaji Vidyapeeth (Deemed-to-be University), Puducherry, India E-mail:
Initial dose of tapentadol and concomitant use of duloxetine are associated with delirium occurring after initiation of tapentadol therapy in cancer patients.
J Opioid Manag
January 2025
Department of Pharmacy, Hyogo Medical University Hospital, Hyogo, Japan.
Objective: Tapentadol causes fewer gastrointestinal adverse events than other potent opioid analgesics because of its low affinity for opioid receptors; however, development of symptoms related to central nervous system disorders, including delirium, has not been well-studied. This study aimed to identify the factors that influence the development of delirium after initiation of tapentadol therapy in hospitalized patients with cancer.
Design: Retrospective study.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!